Vis enkel innførsel

dc.contributor.authorGjerde, Priyanthi Borgenen_US
dc.contributor.authorDieset, Ingriden_US
dc.contributor.authorSimonsen, Carmen Elisabethen_US
dc.contributor.authorHoseth, Eva Zsuzsannaen_US
dc.contributor.authorIversen, Trude Seselie Jahren_US
dc.contributor.authorLagerberg, Trine Viken_US
dc.contributor.authorLyngstad, Siv Hegeen_US
dc.contributor.authorMørch, Ragni Heleneen_US
dc.contributor.authorSkrede, Siljeen_US
dc.contributor.authorAndreassen, Ole Andreasen_US
dc.contributor.authorMelle, Ingriden_US
dc.contributor.authorSteen, Vidar Martinen_US
dc.PublishedGjerde PB, Dieset I, Simonsen CE, Hoseth Ez, Iversen TSJ, Lagerberg TV, Lyngstad SH, Mørch RH, Skrede S, Andreassen OA, Melle I, Steen VM. Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis. Schizophrenia Research. 2018;197:253-260eng
dc.description.abstractBackground A potential link between increase in total cholesterol and triglycerides and clinical improvement has been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug related effects on lipid biosynthesis. We examined whether changes in serum lipids are associated with alleviation of psychosis symptoms after one year of antipsychotic drug treatment in a cohort of first-episode psychosis (FEP) patients. Methods A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)), body mass index (BMI) and clinical state were obtained at baseline and after 12 months. The Positive and Negative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed to examine the relationship between serum lipids and psychotic symptoms while controlling for potential confounders including BMI. Results An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS negative subscores (B = − 0.48, p = 0.03). This relationship was not affected by concurrent change in BMI (adjusted HDL: B = − 0.54, p = 0.02). No significant associations were found between serum lipids, BMI and PANSS positive subscores. Conclusion We found that an increase in HDL level during antipsychotic treatment is associated with improvement in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction between lipid pathways and psychosis.en_US
dc.rightsAttribution CC BY-NC-NDeng
dc.subjectSerum lipidseng
dc.subjectAntipsychotic treatmenteng
dc.subjectClinical outcomeeng
dc.titleIncrease in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)
dc.source.journalSchizophrenia Research
dc.relation.projectStiftelsen Kristian Gerhard Jebsen: SKGJ-MED-008
dc.relation.projectNorges forskningsråd: 223273

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY-NC-ND
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY-NC-ND